October sees a frenzy of biotech IPOs

October sees a frenzy of biotech IPOs October was the busiest month in three years for initial public offerings in the biotechnology sector. But the performance of the newly listed companies has been lacklustre as investors proved wary of betting on businesses that have yet to show a profit.


Venture Financing: Ready To Rebound?

Venture Financing: Ready To Rebound? There’s little doubt that the financing window has opened up, but investors, analysts and biotech companies themselves are still questioning just exactly how wide it will be and how long it will last.


Biotechblog